Global Pulmonary Arterial Hypertension (PAH) Drugs Market - Industry Analysis Size Share Growth Trends and Forecast 2024 - 2031

Global Pulmonary Arterial Hypertension (PAH) Drugs Market - Industry Analysis Size Share Growth Trends and Forecast 2024 - 2031

  • SKU :
    SAC5877257
  • Published Date :
    May 31, 2024
  • Number of Pages :
    350

Product Description

The Pulmonary Arterial Hypertension (PAH) Drugs market was valued at US$ xx in 2023. The market for Pulmonary Arterial Hypertension (PAH) Drugs is projected to grow from US$ xx million in 2024, and is projected to reach xx by 2031, at a CAGR of xx% during the forecast period. Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values are estimated based on manufacturers' revenue.

The report offers detailed coverage of Pulmonary Arterial Hypertension (PAH) Drugs industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Pulmonary Arterial Hypertension (PAH) Drugs by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

In addition to this data, the report provides insight into drivers of market demand and strategies of suppliers. Key players are profiled, and their market shares in the global Pulmonary Arterial Hypertension (PAH) Drugs market are discussed.

The market is segmented by types: 
    Prostacyclin and Prostacyclin Analogs
    SGC Stimulators
    ERA
    PDE-5

It can be also divided by applications:
    Hospital
    Clinic

And this report covers the historical situation, present status and the future prospects of the global Pulmonary Arterial Hypertension (PAH) Drugs market for 2021-2031. In this report, we analyze global market from 5 geographies: Asia-Pacific, Europe, North America, Middle East & Africa, South America.

Finally, the report provides detailed profile and data information analysis of leading company.
    Actelion
    Gilead Sciences
    United Therapeutics
    GlaxoSmithKline
    Pfizer
    Bayer
    Arena

Report Includes:
- xx data tables and xx additional tables
- An overview of global Pulmonary Arterial Hypertension (PAH) Drugs market
- An detailed key players analysis across regions
- Analyses of global market trends, with historical data, estimates for 2024 and projections of compound annual growth rates (CAGRs) through 2031
- Insights into regulatory and environmental developments
- Information on the supply and demand scenario and evaluation of technological and investment opportunities in the Pulmonary Arterial Hypertension (PAH) Drugs market
- Profiles of major players in the industry, including     Actelion,     Gilead Sciences,     United Therapeutics,     GlaxoSmithKline,     Pfizer.....

Research objectives
    To study and analyze the global Pulmonary Arterial Hypertension (PAH) Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2019 to 2021, and Forecast to 2031.
    To understand the structure of Pulmonary Arterial Hypertension (PAH) Drugs market by identifying its various subsegments.
    Focuses on the key global Pulmonary Arterial Hypertension (PAH) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, Porter's five forces analysis, SWOT analysis and development plans in next few years.
    To analyze the Pulmonary Arterial Hypertension (PAH) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
    To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
    To project the consumption of Pulmonary Arterial Hypertension (PAH) Drugs submarkets, with respect to key regions (along with their respective key countries).
    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
    To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Content 

Table of Contents

Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2024, Forecast to 2031

1 Scope of the Study
    1.1 Pulmonary Arterial Hypertension (PAH) Drugs Introduction
    1.2 Research Programs
    1.3 Analysis of Macroeconomic Indicators
    1.4 Years Considered
    1.5 Methodology
    1.6 Data Source
    1.7 Research Objectives

2 Pulmonary Arterial Hypertension (PAH) Drugs Industry Overview
    2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size (Million USD) Comparison by Regions (2024-2031)
        2.1.1 Pulmonary Arterial Hypertension (PAH) Drugs Global Import Market Analysis
        2.1.2 Pulmonary Arterial Hypertension (PAH) Drugs Global Export Market Analysis
        2.1.3 Pulmonary Arterial Hypertension (PAH) Drugs Global Main Region Market Analysis
    2.2 Market Analysis by Type
        2.2.1 Prostacyclin and Prostacyclin Analogs
        2.2.2 SGC Stimulators
        2.2.3 ERA
        2.2.4 PDE-5
    2.3 Market Analysis by Application
        2.3.1 Hospital
        2.3.2 Clinic
    2.4 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, Sales and Market Share by Manufacturer
        2.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Manufacturer (2019-2023)
        2.4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Manufacturer (2019-2023)
        2.4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Industry Concentration Ratio (CR5 and HHI)
        2.4.4 Top 5 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturer Market Share
        2.4.5 Top 10 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturer Market Share
        2.4.6 Date of Key Manufacturers Enter into Pulmonary Arterial Hypertension (PAH) Drugs Market
        2.4.7 Key Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Offered
        2.4.8 Mergers & Acquisitions Planning
    2.5 Pulmonary Arterial Hypertension (PAH) Drugs Historical Development Overview
    2.6 Market Dynamics
        2.6.1 Market Opportunities
        2.6.2 Market Risk
        2.6.3 Market Driving Force
        2.6.4 Porter's Five Forces Analysis
    2.7 Coronavirus Disease 2019 (Covid-19): Pulmonary Arterial Hypertension (PAH) Drugs Industry Impact
        2.7.1 How the Covid-19 is Affecting the Pulmonary Arterial Hypertension (PAH) Drugs Industry
        2.7.2 Pulmonary Arterial Hypertension (PAH) Drugs Business Impact Assessment - Covid-19
        2.7.3 Market Trends and Pulmonary Arterial Hypertension (PAH) Drugs Potential Opportunities in the COVID-19 Landscape
        2.7.4 Measures / Proposal against Covid-19

3 Upstream and Downstream Market Analysis
    3.1 Upstream Analysis
        3.1.1 Macro Analysis of Upstream Markets
        3.1.2 Key Players in Upstream Markets
        3.1.3 Upstream Market Trend Analysis
        3.1.4 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Cost Analysis
    3.2 Downstream Market Analysis
        3.2.1 Macro Analysis of Down Markets
        3.2.2 Key Players in Down Markets
        3.2.3 Downstream Market Trend Analysis
        3.2.4 Sales Channel, Distributors, Traders and Dealers

4 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Categorized by Regions
    4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, Sales and Market Share by Regions
        4.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Regions (2019-2023)
        4.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Regions (2019-2023)
    4.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
    4.3 APAC Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
    4.4 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
    4.5 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
    4.6 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)

5 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size Categorized by Countries
    5.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Market Share by Countries
        5.1.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries (2019-2023)
        5.1.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries (2019-2023)
        5.1.3 Germany Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        5.1.4 UK Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        5.1.5 France Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        5.1.6 Russia Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        5.1.7 Italy Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        5.1.8 Spain Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
    5.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Value) by Manufacturers (2019-2023)
    5.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Market Share by Type (2019-2023)
        5.3.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2019-2023)
        5.3.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Revenue Share by Type (2019-2023)
    5.4 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2019-2023)

6 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size Categorized by Countries
    6.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Market Share by Countries
        6.1.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries (2019-2023)
        6.1.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries (2019-2023)
        6.1.3 China Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        6.1.4 Japan Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        6.1.5 Korea Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        6.1.6 India Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        6.1.7 Southeast Asia Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        6.1.8 Australia Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
    6.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales and Revenue (Value) by Manufacturers (2019-2023)
    6.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Market Share by Type (2019-2023)
        6.3.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2019-2023)
        6.3.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Revenue Share by Type (2019-2023)
    6.4 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Application (2019-2023)

7 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size Categorized by Countries
    7.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Market Share by Countries
        7.1.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries (2019-2023)
        7.1.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries (2019-2023)
        7.1.3 United States Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        7.1.4 Canada Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        7.1.5 Mexico Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
    7.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Value) by Manufacturers (2019-2023)
    7.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Market Share by Type (2019-2023)
        7.3.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2019-2023)
        7.3.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Revenue Share by Type (2019-2023)
    7.4 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2019-2023)

8 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Size Categorized by Countries
    8.1 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Market Share by Countries
        8.1.1 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries (2019-2023)
        8.1.2 South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries (2019-2023)
        8.1.3 Brazil Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
    8.2 South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Value) by Manufacturers (2019-2023)
    8.3 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Market Share by Type (2019-2023)
        8.3.1 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2019-2023)
        8.3.2 South America Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Revenue Share by Type (2019-2023)
    8.4 South America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2019-2023)

9 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size Categorized by Countries
    9.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Market Share by Countries
        9.1.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Countries (2019-2023)
        9.1.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Countries (2019-2023)
        9.1.3 GCC Countries Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        9.1.4 Turkey Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        9.1.5 Egypt Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
        9.1.6 South Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales and Growth Rate (2019-2023)
    9.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue (Value) by Manufacturers (2019-2023)
    9.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales, Revenue and Market Share by Type
        9.3.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2019-2023)
        9.3.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Revenue Share by Type (2019-2023)
    9.4 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2019-2023)

10 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Segment by Type
    10.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, Sales and Market Share by Type (2019-2023)
        10.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales and Market Share by Type (2019-2023)
        10.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue and Market Share by Type (2019-2023)
    10.2 Prostacyclin and Prostacyclin Analogs Sales Growth Rate and Price
        10.2.1 Global Prostacyclin and Prostacyclin Analogs Sales Growth Rate (2019-2023)
        10.2.2 Global Prostacyclin and Prostacyclin Analogs Price (2019-2023)
    10.3 SGC Stimulators Sales Growth Rate and Price
        10.3.1 Global SGC Stimulators Sales Growth Rate (2019-2023)
        10.3.2 Global SGC Stimulators Price (2019-2023)
    10.4 ERA Sales Growth Rate and Price
        10.4.1 Global ERA Sales Growth Rate (2019-2023)
        10.4.2 Global ERA Price (2019-2023)
    10.5 PDE-5 Sales Growth Rate and Price
        10.5.1 Global PDE-5 Sales Growth Rate (2019-2023)
        10.5.2 Global PDE-5 Price (2019-2023)

11 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Segment by Application
    11.1 Global Pulmonary Arterial Hypertension (PAH) DrugsSales Market Share by Application (2019-2023)
    11.2 Hospital Sales Growth Rate (2019-2023)
    11.3 Clinic Sales Growth Rate (2019-2023)

12 Market Forecast for Pulmonary Arterial Hypertension (PAH) Drugs
    12.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue, Sales and Growth Rate (2024-2031)
    12.2 Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast by Regions (2024-2031)
        12.2.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast (2024-2031)
        12.2.2 APAC Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast (2024-2031)
        12.2.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast (2024-2031)
        12.2.4 South America Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast (2024-2031)
        12.2.5 Middle East & Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast (2024-2031)
    12.3 Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast by Type (2024-2031)
        12.3.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Type (2024-2031)
        12.3.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share Forecast by Type (2024-2031)
    12.4 Pulmonary Arterial Hypertension (PAH) Drugs Market Forecast by Application (2024-2031)
        12.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Application (2024-2031)
        12.4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share Forecast by Application (2024-2031)

13 Analysis of Pulmonary Arterial Hypertension (PAH) Drugs Industry Key Manufacturers
    13.1 Actelion
        13.1.1 Company Details
        13.1.2 Product Information
        13.1.3 Actelion Pulmonary Arterial Hypertension (PAH) Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.1.4 Main Business Overview
        13.1.5 Actelion News
    13.2 Gilead Sciences
        13.2.1 Company Details
        13.2.2 Product Information
        13.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.2.4 Main Business Overview
        13.2.5 Gilead Sciences News
    13.3 United Therapeutics
        13.3.1 Company Details
        13.3.2 Product Information
        13.3.3 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.3.4 Main Business Overview
        13.3.5 United Therapeutics News
    13.4 GlaxoSmithKline
        13.4.1 Company Details
        13.4.2 Product Information
        13.4.3 GlaxoSmithKline Pulmonary Arterial Hypertension (PAH) Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.4.4 Main Business Overview
        13.4.5 GlaxoSmithKline News
    13.5 Pfizer
        13.5.1 Company Details
        13.5.2 Product Information
        13.5.3 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.5.4 Main Business Overview
        13.5.5 Pfizer News
    13.6 Bayer
        13.6.1 Company Details
        13.6.2 Product Information
        13.6.3 Bayer Pulmonary Arterial Hypertension (PAH) Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.6.4 Main Business Overview
        13.6.5 Bayer News
    13.7 Arena
        13.7.1 Company Details
        13.7.2 Product Information
        13.7.3 Arena Pulmonary Arterial Hypertension (PAH) Drugs Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.7.4 Main Business Overview
        13.7.5 Arena News

14 Research Findings and Conclusion

15 Appendix

Search results for Pharmaceutical Industry

Select License Type

get a sample
Ask For Customization
Get a quote
Speak to Analyst
Buy Now

Consumer Goods

Medical Devices

Retail

Top Rated Products